

Medical Photonics: Advancing Objective Patient Monitoring, supported by MeTAP

AT A GLANCE


- **Company:** Medical Photonics
- **Sector:** MedTech / Medical Devices
- **MeTAP support accessed:** IP and regulatory consultancy
- **Key outcome:** Clear IP and regulatory roadmap to progress toward clinical validation and market readiness

THE CHALLENGE

Tissue perfusion and the microcirculation are key health indicators, but can be highly subjective and variable, limiting its clinical reliability and adoption.

Medical Photonics is developing an optical-based technology which can objectively measure the microcirculation, unlike the manual methods currently used. Removing subjectivity and providing standardised data that can support faster and more confident clinical decision-making.

As an early-stage innovation with strong clinical interest, Medical Photonics reached a critical point where specialist intellectual property and regulatory expertise were needed to protect the technology, embed compliance early, and de-risk progression toward clinical studies and market approval.



METAP SUPPORT

Through MeTAP, Medical Photonics accessed tailored consultancy support including:

- IP consultancy to review the patent landscape, assess freedom to operate, and define a robust protection strategy around perfusion and microcirculation.
- Regulatory strategy support to establish the correct device classification, applicable standards, and documentation required for EU MDR approval, with future UKCA and FDA pathways identified

This early expert input ensured that IP protection and regulatory compliance were embedded into development from the outset.

As part of the wider support enabled through MeTAP, Medical Photonics also attended International Health Day in Vienna, following an introduction to Advantage Austria through the programme. The visit provided valuable opportunities to build international connections and explore relevant clinical and research activity.

A key highlight was an excursion to the Medical University of Vienna, where the team learned more about their work using Optical Coherence Tomography (OCT) in ophthalmology. This was particularly relevant to Medical Photonics' own focus on optical technologies and helped broaden their understanding of how advanced optical methods are being applied in healthcare settings.

IMPACT & OUTCOMES

Since accessing MeTAP support, Medical Photonics has strengthened the foundations needed to progress beyond prototype stage.

Outcomes to date include:

- A clearer and more robust IP position to protect core innovation
- A defined regulatory pathway aligned with EU MDR requirements
- Reduced commercial and regulatory risk ahead of clinical studies and investment discussions.

Access to MeTAP support came at a crucial stage for Medical Photonics. It provided confidence and clarity to strengthen its IP position and plan the next steps toward market readiness.

ADDED VALUE OF METAP

Accessing specialist IP and regulatory expertise at this stage would have been challenging without MeTAP support. The programme helped Medical Photonics establish a clear, de-risked pathway toward clinical validation and market entry, strengthening investor readiness and strategic planning.

MeTAP gave access to specialist support at exactly the right stage, helping de-risk development and move forward with greater confidence.

LOOKING AHEAD

Next steps include progressing into pilot clinical studies, completing patent filings and the technical file, and continuing to build the regulatory pathway alongside partnership and commercial discussions.

SME PERSPECTIVE

“Engage early with support like MeTAP, as the right expert input at the right stage can save time, reduce risk and strengthen your path to market.”

Brett Gadsby, COO, Medical Photonics Ltd



Nottingham
City Council



Funded by
UK Government



University of
Nottingham
UK | CHINA | MALAYSIA